AKESO's stock plummeted 5.69% during intraday trading, giving back gains from the previous session.

The sharp decline comes despite the recent release of positive Phase II clinical data for its PD-1/CTLA-4 bispecific antibody at a major medical conference. Market participants have raised concerns over the company's broader fundamentals, including questions about the differentiation of its pipeline versus combination therapies, reported friction with its commercialization partner, and a cash runway estimated at slightly over one year, which overshadowed the favorable clinical results.